SEARCH

SEARCH BY CITATION

References

  • 1
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 2
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 32333.
  • 3
    Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med 2001; 345: 1098104.
  • 4
    Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis 2004; 10: 65760.
  • 5
    Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48: 31924.
  • 6
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 50739.
  • 7
    Strader DB, Wright TL, Thomas DL, Seeff LB. Diagnosis, management and treatment of hepatitis C. ASSLD practice guidelines. Hepatology 2004; 39: 1147.
  • 8
    Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006; 4: 107681.
  • 9
    Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54: 1597603.
  • 10
    Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplant outcome. Hepatology 1999; 29: 25763.
  • 11
    Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 2536.
  • 12
    Del Valle García-Sánchez M, Gómez-Camacho F, Poyato-González A, Iglesias-Flores EM, De Dios-Vega JF, Sancho-Zapatero R. Infliximab therapy in a patient with Crohn’s disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004; 10: 7012.
  • 13
    Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62: 6867.
  • 14
    Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 2004; 53: 13635.
  • 15
    Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn’s disease: need for HBV-screening? World J Gastroenterol 2006; 12: 9746.
  • 16
    Ueno Y, Tanaka S, Shimamoto M, et al. Infliximab therapy for Crohn’s disease in a patient with chronic hepatitis B. Dig Dis Sci 2005; 50: 1636.
  • 17
    Wendling D, Auge B, Bettinger D, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64: 7889.
  • 18
    Anelli MG, Torres DD, Manno C, et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 2005; 52: 251920.
  • 19
    Sakellariou GT, Chatzigiannis I. Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 2007; 26: 9502.
  • 20
    Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007; 13: 5089.
  • 21
    Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn’s disease. Inflamm Bowel Dis 2007; 13: 14534.
  • 22
    Montiel PM, Solis JA, Chirinos JA, Casis B, Sánchez F, Rodríguez S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008; 28: 71820.
  • 23
    Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab. J Gastroenterol 2008; 43: 397401.
  • 24
    Benucci M, Manfredi M, Mecocci L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol 2008; 14: 2456.
  • 25
    Robinson H, Walker-Bone K. Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford) 2009; 48: 44850.
  • 26
    Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still’s disease. J Rheumatol 2003; 30: 16245.
  • 27
    Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab,etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol 2009; 28: 78791.
  • 28
    Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008; 35: 4214.
  • 29
    Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clin Rheumatol 2008; 27: 106971.
  • 30
    Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63(Suppl 2): ii1824.
  • 31
    Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31: 1079.
  • 32
    Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006; 45: 12947.
  • 33
    Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn’s Colitis 2009; 3: 4791.
  • 34
    Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008; 57: 54958.
  • 35
    Lebwohl M, Bagel J, Gelfand JM, et al. From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008; 58: 94105.
  • 36
    Furst DE, Keystone EC, Kirkham B, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008; 67: iii225.
  • 37
    Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49: 6527.
  • 38
    Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 226.
  • 39
    Esteve M, Loras C, González-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treatedCrohn’s disease patient. Inflamm Bowel Dis 2007; 13: 14501.
  • 40
    De Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. Consensus Statement. J Hepatol 2003; 39(Suppl1): S325.
  • 41
    Fukuda R, Ishihara S, Chowdhury A, et al. Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C. Liver 1996; 16: 3909.
  • 42
    Kliem V, Hoff U, Brunkhorst R, et al. The long-term course of HCV after kidney transplantation. Transplantation 1996; 62: 1417.
  • 43
    Campbell S, Ghosh S. Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001; 13: 1912.
  • 44
    Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004; 51: 8004.
  • 45
    Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn’s disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 2003; 98: 5045.
  • 46
    Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004; 51: 5804.
  • 47
    Aslanidis S, Vassiliadis T, Pyrpasopoulou A, Douloumpakas I, Zamboulis C. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007; 26: 2614.
  • 48
    Marotte H, Fontanges E, Bailly F, Zoulim F, Trepo C, Miossec P. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 2007; 46: 979.
  • 49
    Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62: 107882.
  • 50
    Niewold TB, Gibofsky A. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum 2006; 54: 23357.
  • 51
    Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 2006; 54: 3612.
  • 52
    De Simone C, Paradisi A, Capizzi R, Carbone A, Siciliano M, Amerio PL. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006; 54: 11024.
  • 53
    Cassano N, Vena GA. Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection. Int J Dermatol 2008; 47: 9801.
  • 54
    Cecchi R, Bartoli L. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). Dermatol Online J 2006; 12: 4.
  • 55
    Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008; 35: 19449.
  • 56
    Linardaki G, Katsarou O, Ioannidou P, Karafoulidou A, Boki K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007; 34: 13535.
  • 57
    Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 2008; 8: 1046.
  • 58
    Abdelmalek MF, Liu C, Valentine JF. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn’s disease. Am J Gastroenterol 2007; 102: 13334.
  • 59
    Bellisai F, Giannitti C, Donvito A, Galeazzi M. Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 2007; 26: 11279.
  • 60
    Alcaide AJ, Barrera MV, Habicheyn S, López N, Mendiola MV, Herrera E. Safety of etanercept therapy in a patient with psoriasis, Down’s syndrome and concomitant hepatitis C virus infection. J Eur Acad Dermatol Venereol 2008; 22: 15146.
  • 61
    Zein NN; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 31522.
  • 62
    Kyrlagkitsis I, Portmann B, Smith H, O’Grady J, Cramp ME. Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT. Am J Gastroenterol 2003; 98: 158893.
  • 63
    De Moliner L, Pontisso P, De Salvo GL, Cavalletto L, Chemello L, Alberti A. Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut 1998; 42: 85660.
  • 64
    Vauloup C, Krzysiek R, Greangeot-Keros L, et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 2006; 17: 2903.
  • 65
    Scherzer TM, Staufer K, Novacek G, et al. Efficacy and safety of antiviral therapy in patients with Crohn’s disease and chronic hepatitis C. Alimentary Pharmacol Ther 2008; 28: 7428.
  • 66
    Ito M, Baba M, Sato A, et al. Tumor necrosis factor enhances replication of human immunodeficiency virus (HIV) in vitro. Biochem Biophys Res Commun 1989; 158: 30712.
  • 67
    Aboulafia DM, Bundow D, Wilske K, Ochs UI. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000; 75: 10938.
  • 68
    Walker RE, Spooner KM, Kelly G, et al. Inhibition of immunoreactive tumor necrosis factor-a by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis 1996; 174: 638.
  • 69
    Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004; 18: 25764.
  • 70
    Beltrán B, Nos P, Bastida G, Iborra M, Hoyos M, Ponce J. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn’s disease. Gut 2006; 55: 16701.
  • 71
    Sellam J, Bouvard B, Masson C, et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine 2007; 74: 197200.
  • 72
    Filippi J, Roger PM, Schneider SM, et al. Infliximab and human immunodeficiency virus infection: viral load reduction and CD4+ T-cell loss related to apoptosis. Arch Intern Med 2006; 166: 17834.
  • 73
    Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67: 7102.
  • 74
    Kaur PP, Chan VC, Berney SN. Successful etanercept use in an HIV-positive patient with rheumatoid arthritis. J Clin Rheumatol 2007; 13: 7980.
  • 75
    Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter’s syndrome. J Rheumatol 2003; 30: 40711.
  • 76
    Bartke U, Venten I, Kreuter A, Gubbay S, Altmeyer P, Brockmeyer NH. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br J Dermatol 2004; 150: 7846.
  • 77
    Mikhail M, Weinberg JM, Smith BL. Successful treatment with etanercept of von Zumbusch Pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol 2008; 144: 4536.
  • 78
    CDC. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR 2000; 49: 1125.
  • 79
    Masur H, Kaplan JE, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002; 137: 43578.
  • 80
    Wong GH, Goeddel DV. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature 1986; 323: 81922.
  • 81
    US Food and Drug Administration Center for Drug Evaluation and Research Website [Accessed July 28th 2008] (Available at: http://www.fda.gov/cder/aers/extract.htm)
  • 82
    Skripak JM, Rodgers GL, Martucci C, et al. Disseminated herpes simplex (HSV) infection precipitating macrophage activation syndrome (MAS) in a child with systemic juvenile idiopathic arthritis (SJIA) undergoing therapy with infliximab [abstract]. Pediatr Rheumatol Online J 2003; 1: S58.
  • 83
    Van Der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, Van Der Spoel JI, Wester JP, Zandstra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 2003; 29: 23279.
  • 84
    Wendling D, Streit G, Toussirot E, Prati C. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine 2008; 75: 5403.
  • 85
    Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 73744.
  • 86
    Becart S, Segaert S. Recurrent varicella in an adult psoriasis patient treated with etanercept. Dermatology 2008; 217: 2601.
  • 87
    Kinder A, Stephens S, Mortimer N, Sheldon P. Severe herpes zoster after infliximab infusion. Postgrad Med J 2004; 80: 26.
  • 88
    Balato N, Gaudiello F, Balato A, Ayala F. Development of primary varicella infection during infliximab treatment for psoriasis. J Am Acad Dermatol 2009; 60: 70910.
  • 89
    Lee DH, Kim HS, Song YW, Cho KH. Development of varicella during adalimumab therapy. J Eur Acad Dermatol Venereol 2007; 21: 6878.
  • 90
    Choi HJ, Kim MY, Kim HO, Park YM. An atypical varicella exanthem associated with the use of infliximab. Int J Dermatol 2006; 45: 9991000.
  • 91
    Leung VS, Nguyen MT, Bush TM. Disseminated primary varicella after initiation of infliximab for Crohn’s disease. Am J Gastroenterol 2004; 99: 25034.
  • 92
    Vonkeman H, Ten Napel C, Rasker H, Van De Laar M. Disseminated primary varicella infection during infliximab treatment. J Rheumatol 2004; 31: 25178.
  • 93
    Sari I, Birlik M, Gonen C, et al. Cytomegalovirus colitis in a patient with Behcet’s disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol 2008; 14: 29124.
  • 94
    Kohara MM, Blum RN. Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody. Clin Infect Dis 2006; 42: 7334.
  • 95
    Haerter G, Manfras BJ, De Jong-Hesse Y, et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis 2004; 39: e8894.
  • 96
    Mizuta M, Schuster MG. Cytomegalovirus hepatitis associated with use of anti-tumor necrosis factor-alpha antibody. Clin Infect Dis 2005; 40: 10712.
  • 97
    Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn’s disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2002; 14: 13935.
  • 98
    Lavagna A, Bergallo M, Daperno M, et al. Infliximab and the risk of latent viruses reactivation in active Crohn’s disease. Inflamm Bowel Dis 2007; 13: 896902.
  • 99
    Torre-Cisneros J, Del Castillo M, Castón JJ, Castro MC, Pérez V, Collantes E. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 11325.
  • 100
    D’Ovidio V, Vernia P, Gentile G, et al. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. J Clin Virol 2008; 43: 1803.
  • 101
    Epstein–Barr virus and lymphoproliferative disorders after transplantation . Am J Transplant 2004; 4(Suppl 10): 5965.
  • 102
    Human papillomavirus infection. Am J Transplant 2004; 4(Suppl 10): 95100.
  • 103
    Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn’s disease: A meta-analysis. Gastroenterology 2008; 134(suppl1): A144.
  • 104
    Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT Registry. Clin Gastroenterol Hepatol 2006; 4: 62130.
  • 105
    Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 31518.
  • 106
    Wolfe F, Michaud K. The effect of methotrexate and antitumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007; 56: 14339.
  • 107
    Komatsuda A, Wakui H, Nimura T, Sawada K. Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. Mod Rheumatol 2008; 18: 3158.
  • 108
    Park SH, Kim CG, Kim JY, Choe JY. Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment. Rheumatol Int 2008; 28: 4757.
  • 109
    Reijasse D, Le Pendeven C, Cosnes J, et al. Epstein-Barr virus viral load in Crohn’s disease: effect of immunosuppressive therapy. Inflamm Bowel Dis 2004; 10: 8590.
  • 110
    Balandraud N, Guis S, Meynard JB, Auger I, Roudier J, Roudier C. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 7627.
  • 111
    Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003; 36: 6326.
  • 112
    Kane S, Khatibi B, Reddy D. Higher incidence of abnormal pap smears in women with inflammatory bowel disease. Am J Gastroenterol 2008; 103: 63163.
  • 113
    Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology 2009; 136: 4518.
  • 114
    Fireman B, Kane S, Herrinton LJ. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 598605.
  • 115
    Somasekar A, Alcolado R. Genital condylomata in a patient receiving infliximab for Crohn’s disease. Postgrad Med J 2004; 80: 3589.
  • 116
    Antoniou C, Kosmadaki MG, Stratigos AJ, Katsambas AD. Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology 2008; 216: 3645.
  • 117
    Cohen CD, Horster S, Sander CA, Bogner JR. Kaposi’s sarcoma associated with tumour necrosis factor alpha neutralizing therapy. Ann Rheum Dis 2003; 62: 684.
  • 118
    Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev 2003; 16: 35764.
  • 119
    Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 67792.
  • 120
    Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101: 183440.
  • 121
    Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34: 2729.
  • 122
    Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 92936.